Read by QxMD icon Read

Journal of Gastrointestinal Oncology

Guillaume Le Baut, Jean-Marc Guilloit, Vincent Leprince, Yann Ollivier, Catherine Dubos-Arvis, Pascal Do, Jasmine Sutter, Ludovic Loge, Radj Gervais
Oxaliplatin given systemically is associated with pneumonitis in less than 1% of cases. This case report describes acute respiratory failure, due to bronchiolitis organising pneumonia, in a patient with colorectal carcinoma being treated with hyperthermic intraperitoneal chemotherapy which included oxaliplatin and CPT-11 (irinotecan). The clinical course, the lack of an identifiable infectious agent and the complete response to corticosteroids suggested a drug-induced cause. After ruling out CPT-11, oxaliplatin was considered to be the causal agent...
June 2018: Journal of Gastrointestinal Oncology
Ker-Kan Tan, Violeta Lopez, Mee-Lian Wong, Gerald Choon-Huat Koh
First degree relatives (FDRs) of colorectal cancer (CRC) patients are at higher risks of developing the disease, but screening rates amongst this group remains dismal. We undertook a systematic review of qualitative studies to identify the barriers surrounding CRC screening among FDRs from both the FDRs' and the healthcare professionals' perspectives. A comprehensive search of major bibliographic databases from January 2000 till February 2017 was performed to answer the above research questions. Pre-determined inclusion and exclusion criteria were applied...
June 2018: Journal of Gastrointestinal Oncology
Amitabh Thacoor
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. The stomach is most commonly affected. Advances in immunopathology have identified a mutation in the c-KIT proto-oncogene, leading to the development of the tyrosine-kinase inhibitor Imatinib as targeted therapy for advanced disease. Surgery, however, remains the only curative treatment of resectable primary GIST. This review article aims at reviewing the management of primary GISTs, investigating recurrences, exploring the role of surgery in metastatic disease and looking into combined surgery and molecular therapy for GISTs...
June 2018: Journal of Gastrointestinal Oncology
Jeremy Chuang, Jun Gong, Samuel J Klempner, Yanghee Woo, Joseph Chao
The multidisciplinary management of locoregional esophagogastric cancers (GCs) has evolved significantly over the past two decades. While perioperative chemotherapy, adjuvant chemotherapy, and postoperative chemotherapy with chemoradiation (CRT) have demonstrated improved survival when compared to surgery alone, there is no universal standard for resectable gastroesophageal cancer. Current global management patterns vary by geographic region, partly related to phase III data originating from each global region...
June 2018: Journal of Gastrointestinal Oncology
Florencia Neffa, Lucia Garcia, Adriana Della Valle, Florencia Carusso, Carolina Vergara, Daniel Sanchez, Marta Sapone, Noelia Silveyra, Ana Laura Revello, Patricia Esperon
Familial adenomatous polyposis (FAP) is an autosomal dominant genetic condition, caused by mutations in the adenomatous polyposis coli ( APC ) tumor suppressor gene. Desmoid tumors (DTs) are seen in 15% to 20% of FAP patients. Specific location of mutation serves as a guide to predict colonic and extra colonic manifestations and their aggressiveness. A severe FAP-phenotypic family was registered in a genetic counselling high-risk Uruguayan hereditary cancer clinic. Proband's DNA was analysed by NGS, detecting a pathogenic mutation in APC gene...
June 2018: Journal of Gastrointestinal Oncology
Jessica M Frakes, Yazan A Abuodeh, Arash O Naghavi, Michelle I Echevarria, Ravi Shridhar, Mark Friedman, Richard Kim, Ghassan El-Haddad, Bela Kis, Benjamin Biebel, Jennifer Sweeney, Junsung Choi, Daniel Anaya, Anna R Giuliano, Sarah E Hoffe
Background: Viral associated (VA) malignancies have recently been correlated with improved outcomes. We sought to evaluate outcomes of patients with hepatocellular carcinoma (HCC) with and without viral hepatitis (hepatitis B and C) treated with lobar yttrium-90 radioembolization (Y-90 RE). Methods: After IRB approval, an institutional database of patients with HCC who received RE between 2009-2014 was queried and 99 patients were identified that received a total of 122 lobar RE...
June 2018: Journal of Gastrointestinal Oncology
Andrew R Kolarich, Jehan L Shah, Thomas J George, Steven J Hughes, Christiana M Shaw, Brian S Geller, Joseph R Grajo
Background: Surgical resection is the standard of care for intrahepatic cholangiocarcinoma (ICC), but only a minority of patients are managed surgically. Other modalities, including external beam radiation (XRT), radiofrequency ablation (RFA), and radioactive implants (RIs) have been employed with significant heterogeneity of prognosis reported in the literature. The aim of this study was to evaluate the demographics of patients with ICC managed non-surgically and compare prognosis in patients managed surgically to those that underwent XRT, RFA, or RI...
June 2018: Journal of Gastrointestinal Oncology
Vivek Verma, Adams Kusi Appiah, Tim Lautenschlaeger, Sebastian Adeberg, Charles B Simone, Chi Lin
Background: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. Methods: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT...
June 2018: Journal of Gastrointestinal Oncology
Rebecca Zhu, Fangfang Liu, Gabriella Grisotti, Javier Perez-Irizarry, Ronald R Salem, Charles H Cha, Kimberly L Johung, Daniel J Boffa, Yawei Zhang, Sajid A Khan
Background: Adjuvant therapy for gastric adenocarcinoma has shown a survival advantage, though it may be underutilized. The purpose of this study is to examine how infrequently adjuvant therapy is administered with curative intent gastrectomy for node positive gastric cancer and the long-term effects to patients. Methods: The National Cancer Database was queried from 2006-2013 for patients with node positive gastric adenocarcinoma undergoing a potentially curative gastrectomy...
June 2018: Journal of Gastrointestinal Oncology
Emmanuel Gabriel, Sumana Narayanan, Kristopher Attwood, Steven Hochwald, Moshim Kukar, Steven Nurkin
Background: The purpose of this study was to characterize disparities among centers performing major surgery for esophageal or gastric cancer stratified by case volume. Methods: The National Cancer Data Base (NCDB) was queried for cases of esophagectomy or total gastrectomy. Centers were compared based on number of cases during 2004-2013: low volume [1-99], middle [100-200], and high [>200]. Results: For esophagectomy, 17,547 patients were included; 73...
June 2018: Journal of Gastrointestinal Oncology
Nizar Bhulani, Arjun Gupta, Ang Gao, Jenny Li, Chad Guenther, Chul Ahn, Elizabeth Paulk, Stephanie Houck, Muhammad S Beg
Background: Palliative care has been associated with improved survival and quality of life, with lower rate of end-of-life health care utilization and cost. We examined trends in palliative care utilization in older pancreatic cancer patients. Methods: Pancreatic cancer patients with and without palliative care consults were identified using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database between 2000 and 2009. Trend of palliative care use was studied...
June 2018: Journal of Gastrointestinal Oncology
William H Jin, Sarah E Hoffe, Ravi Shridhar, Tobin Strom, Puja Venkat, Gregory M Springett, Pamela J Hodul, Jose M Pimiento, Kenneth L Meredith, Mokenge P Malafa, Jessica M Frakes
Background: The appropriate adjuvant treatment for resected pancreatic cancer remains a controversy. We sought to determine the effect of adjuvant treatment on overall survival (OS) in patients with pancreatic tail adenocarcinoma. Methods: Retrospective review of patients with upfront surgically resected pancreatic tail cancer treated at our institution between 2000-2012 was performed to determine outcomes of patients treated with and without adjuvant radiation therapy (RT)...
June 2018: Journal of Gastrointestinal Oncology
Joey Mercier, Ioannis A Voutsadakis
Background: The cancer micro-environment is recognized as having an increasing importance in cancer progression. Immune cells originating from the peripheral blood are important elements of this environment. Thrombocytosis, neutrophilia and lymphocytopenia have been found to be negative prognostic indicators in many cancers. This study aims to evaluate the potential of the use of a novel hematological marker, the platelet-neutrophil to lymphocyte ratio (PNLR) as a practical, reliable, and inexpensive prognostic tool in metastatic colorectal adenocarcinomas...
June 2018: Journal of Gastrointestinal Oncology
Waqar Haque, Vivek Verma, E Brian Butler, Bin S Teh
Background: Chemoradiotherapy for anal cancer (AC) can incur substantial treatment-related toxicities. Whereas radiotherapy (RT) for AC has historically been delivered with two- or three-dimensional conformal RT (2D/3DCRT) techniques, intensity-modulated RT (IMRT) is associated with improved target conformality and lower doses to organs-at-risk (OARs). This is the first investigation to date evaluating trends of IMRT utilization in the United States. Methods: The National Cancer Data Base (NCDB) was queried [2004-2015] for AC patients receiving definitive chemoradiotherapy with a defined RT technique (3DCRT versus IMRT)...
June 2018: Journal of Gastrointestinal Oncology
Hossein-Ali Nikbakht, Haleh Ghaem, Javad Shokri-Shirvani, Saber Ghaffari-Fam, Sedigheh Alijanpour
Background: Colorectal cancer (CRC) is one of the most common types of gastrointestinal cancers. This study aimed to determine the demographic characteristics and their relationships with the results of the first screening program for CRC in people over 50 years old in northern Iran. Methods: This cross-sectional study was conducted in 2016 on 924 eligible people over 50 years old. Initial screening was done by IFOBT and then colonoscopy was performed if the results were positive...
June 2018: Journal of Gastrointestinal Oncology
Meysam Mosallaei, Miganoosh Simonian, Fateme Ahangari, Maryam Miraghajani, Deniz Mortazavi, Ahmad Reza Salehi, Sharifeh Khosravi, Rasoul Salehi
Background: Genetic determinants are considered as driving forces in development colorectal cancer (CRC), a malignancy that ranks as the second cause of cancer death in the world. Single nucleotide polymorphisms (SNPs), are considered as the main genetic factor in cancers susceptibility. MicroRNAs are critical players in posttranslational gene regulation by binding to their specific recognition sequences located at 3' untranslated region (UTR) of mRNAs. In present study we have elucidated the role of 9,850 A > G (rs4648298), in development of sporadic CRC in Iranian population...
June 2018: Journal of Gastrointestinal Oncology
Jehan Belal Yahya, Daniel O Herzig, Matthew Joseph Farrell, Catherine R Degnin, Yiyi Chen, John Holland, Simon Brown, Jerry Jaboin, Vassiliki Liana Tsikitis, Kim Lu, Charles R Thomas, Timur Mitin
Background: Management of rectal cancer with involved lateral pelvic lymph nodes (LPLNs) at the time of diagnosis-the stage we refer institutionally to as Stage 3.5-is controversial. The American Joint Committee on Cancer's 7th edition classifies internal iliac lymph nodes (LNs) as regional (Stage III), but both external and common iliac LNs as metastatic (Stage IV). However, in many Asian countries all LPLNs are considered regional and patients are treated with curative intent, with literature supporting improved outcomes with LPLN dissection...
June 2018: Journal of Gastrointestinal Oncology
Jehan Belal Yahya, Matthew Joseph Farrell, Daniel O Herzig, Catherine R Degnin, Yiyi Chen, John Holland, Simon Brown, Jerry Jaboin, Charles R Thomas, Timur Mitin
Background: Accurate staging is crucial for management of patients with newly diagnosed rectal cancer. Endorectal ultrasound (EUS) has been the standard modality in the United States for decades, with magnetic resonance imaging (MRI) now preferred by national guidelines. Positron emission tomography (PET), conversely, is not recommended. The current utilization of imaging modalities by American radiation oncologists in staging newly diagnosed rectal cancer is unknown. Methods: American radiation oncologists completed an anonymous institutional review board-approved online survey probing their imaging preferences for initial staging of rectal cancer patients...
June 2018: Journal of Gastrointestinal Oncology
Kanyarat Katanyoo, Imjai Chitapanarux, Tharatorn Tungkasamit, Somvilai Chakrabandhu, Marisa Chongthanakorn, Rungarun Jiratrachu, Apiradee Kridakara, Kanokpis Townamchai, Pooriwat Muangwong, Chokaew Tovanabutra, Kittisak Chomprasert
Background: Adjuvant chemotherapy at concurrent time with radiation therapy (RT) or at adjuvant time alone in locally advanced rectal cancer (LARC) is used with several regimens. The cost-utility analysis was conducted to compare administration of two 5-FU regimens and capecitabine in the aspect of provider and societal viewpoint. Methods: Stage II or III rectal cancer patients who received pre-operative or post-operative concurrent chemoradiotherapy and adjuvant chemotherapy were compared by using decision tree model between (I) 5-FU plus leucovorin (LV) for 5 days per cycle (Mayo Clinic regimen); (II) 5-FU continuous infusion (CI) for 120-h per cycle (CAO/ARO/AIO-94 protocol); (III) standard regimen of capecitabine...
June 2018: Journal of Gastrointestinal Oncology
Moh'd Khushman, Girijesh Kumar Patel, Peter Joel Hosein, Javier Ariel Laurini, Daniel Cameron, David Roland Clarkson, Thomas Wayne Butler, Carole Wiseman Norden, Wilma Baliem, Vanessa Jones, Sanjyot Bhadkamkar, Cindy Nelson, Frances Lee, Ajay P Singh, William R Taylor
Background: The correlation between DPYD*9A (c.85T>C) genotype and dihydropyrimidine dehydrogenase (DPD) deficiency clinical phenotype is controversial. Reference laboratories either did not perform DPYD*9A genotyping or have stopped DPYD*9A genotyping and limited genotyping to high-risk variants (DPYD*2A, DPYD*13 and DPYD*9B) only. This study explored DPYD*9A genotype and clinical phenotype correlation in patients with gastrointestinal (GI) malignancies treated with fluoropyrimidines...
June 2018: Journal of Gastrointestinal Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"